Ramsey Baghdadi
Health care reform is coming.
Preparing for Health Care Reform: Why Big Pharma Thinks it Can Avoid Another "Hillarycare"
Should a Democrat take the White House next January, top pharmaceutical executives expect a serious push for health care reform. The prospect of a health care reform debate triggers the specter of a single-payor, government-run system with price controls. But Democrats are singing a surprisingly soothing tune.
More from Market Access
More from Pink Sheet
• By
While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.
• By
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
• By
The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.